FDA advisers back Gilead's cystic fibrosis drug

12/10/2009 | Reuters

An FDA panel recommended approval of Gilead Sciences' cystic fibrosis drug aztreonam to treat lung infections caused by common Pseudomonas aeruginosa bacteria in CF patients. The advisers found the treatment safe and effective when administered in 75-milligram doses three times daily.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA